Indication
Large B-Cell
32 clinical trials
54 products
5 drugs
Clinical trial
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)Status: Completed, Estimated PCD: 2021-09-24
Product
Lisocabtagene maraleucelProduct
Zilovertamab VedotinClinical trial
A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)Status: Recruiting, Estimated PCD: 2026-01-26
Clinical trial
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular LymphomaStatus: Terminated, Estimated PCD: 2023-12-12
Product
RituximabProduct
CC-292Product
CC-122Product
CC-223Product
ZilovertamabProduct
PrednisoneProduct
PrednisoloneProduct
CyclophosphamideProduct
DoxorubicinProduct
Rituximab BiosimilarProduct
JCAR017Product
DurvalumabClinical trial
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)Status: Completed, Estimated PCD: 2023-02-15
Product
IbrutinibProduct
RelatlimabProduct
CC-99282Product
CC-220Product
NivolumabClinical trial
A Phase Ib Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Patients With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-06-19
Product
Polatuzumab VedotinProduct
VenetoclaxClinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-03-06
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety of SGN-35T in Adults With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2027-06-30
Product
SGN-35TClinical trial
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Status: Active (not recruiting), Estimated PCD: 2023-04-10
Product
SEA-CD40Product
LOXO-305Product
Sepantronium BromideClinical trial
A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.Status: Terminated, Estimated PCD: 2021-07-12
Product
PembrolizumabProduct
BendamustineProduct
PlaceboClinical trial
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2024-08-01
Product
FludarabineProduct
Relmacabtagene AutoleucelProduct
GemcitabineProduct
Nab-paclitaxelClinical trial
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell LymphomaStatus: Completed, Estimated PCD: 2019-03-15
Product
vincristineProduct
lenalidomideProduct
prednisoneClinical trial
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2019-05-27
Clinical trial
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell LymphomaStatus: Completed, Estimated PCD: 2022-04-24
Product
VincristineProduct
LenalidomideClinical trial
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus: Recruiting, Estimated PCD: 2023-12-31
Product
ObinutuzumabProduct
CD19 CAR-T cellsClinical trial
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient SettingStatus: Completed, Estimated PCD: 2023-09-22
Clinical trial
A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell LymphomaStatus: Completed, Estimated PCD: 2022-05-23
Product
DiphenhydramineProduct
ParacetamolClinical trial
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2018-06-01
Product
ASN002Product
Lisocabtagene MaraleucelClinical trial
Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-CellStatus: Active (not recruiting), Estimated PCD: 2020-12-30
Product
R-CHOPClinical trial
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2026-09-15
Product
GlofitamabProduct
PolatuzumabDrug
VarlilumabDrug
cyclophosphamideClinical trial
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial ReleaseStatus:
Clinical trial
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Anti Cluster of Differentiation Antigen 19 (Anti-CD19) Chimeric Antigen Receptor T (CAR T) Cell Therapy With Kymriah/tIsagenlecleucel (LOKI)Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase 1, Open-label Study to Evaluate SGN-35C in Adults With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2028-02-28
Product
SGN-35CClinical trial
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2024-01-15
Clinical trial
A Cancer Research Phase I/ II Trial of ALETA-001 in Participants Who Do Not Achieve or Maintain an Optimal Response to Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-12-01
Product
ALETA-001Clinical trial
A Prospective Multicenter Phase 2 Study of the Chemotherapy-light Combination of Intravenous Rituximab With the Antibody-drug Conjugate Polatuzumab Vedotin and the Bispecific Antibody Glofitamab in Previously Untreated Aggressive B-cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOPStatus: Recruiting, Estimated PCD: 2027-09-30
Product
Polatuzumab vedotinClinical trial
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCLStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Drug
OrelabrutinibClinical trial
Chidamide Combined With R-GemOx(Rituximab、Gemcitabine Plus Oxaliplatin) Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: a Multi-center, Single Arm, Phase II StudyStatus: Completed, Estimated PCD: 2022-11-16
Product
ChidamideClinical trial
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated LymphomasStatus: Active (not recruiting), Estimated PCD: 2020-11-30
Drug
FilgrastimProduct
EPOCHClinical trial
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL Trial)Status: Active (not recruiting), Estimated PCD: 2023-02-28
Product
NebivololClinical trial
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-01-31
Product
R-CHOEPDrug
DA-EPOCH-R